Please assess the completion status of the following clinical trial:

Trial Title: Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Patients with clinical suspicion of pancreatic head cancer who are scheduled to undergo surgical intervention with curative intent~* World Health Organization (WHO) performance score 0-2.~* Signed written informed consent~Exclusion Criteria:~* Medical or psychiatric conditions that compromise the patient's ability to give informed consent.~* Other invasive malignancy~* Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre- menopausal women with intact reproductive organs and women less than two years after menopause.~* Prior neo-adjuvant chemo- of radiotherapy~* History of infusion reactions to bevacizumab or other monoclonal antibody therapies.~* Inadequately controlled hypertension with or without current antihypertensive medications~* Within 6 months prior to inclusion: myocardial infarction, Transient Ischemic Attack, Cerebral Vascular Accident, pulmonary embolism, uncontrolled chronic hepatic failure, unstable angina pectoris.~* Anticoagulant therapy with vitamine K antagonists~* Patients receiving Class 1A (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents~* Evidence of QTc (corrected QT interval) prolongation on pretreatment ECG (greater than 44ms in males of greater than 450ms in females)~* Magnesium, potassium and calcium below the lower limit of normal range.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Bevacizumab-800CW

Based on this trial design, predict the completion outcome and termination type (if applicable).